Anti-tumor activity of immune cells can be restored

December 10, 2013

The Leuven-based VIB researchers have revealed a mechanism that explains why the anti-tumor activity of specific immune cells called macrophages is suppressed during tumor growth. They have also demonstrated that blocking the protein Nrp1 can restore this anti-tumor immune response. This is a first. Nrp1 may provide an important hub for the development of new therapies against cancer.

Max Mazzone: "For many years the biological processes which lead to the coordinated navigation of and nerves have been studied. The first observations come, in fact, from the Belgian anatomist Andreas Vesalius. So we were surprised to discover that immune cells follow the same

signals of blood vessels and nerves to position themselves within the cell and, in doing so, contribute to . By blocking these signals, we can once again turn the against the tumor."

Macrophages and cancer

Macrophages are important cells within the immune system. Among other things, they are responsible for cleaning up pathogens, such as bacteria and viruses. Macrophages, however, also appear to play an important and complex role in the occurrence and metastatization of cancer.

Macrophages that migrate to the tumor are called tumor-associated or TAMs for short. Extensive infiltration of TAMs into the tumor is often correlated with a poor prognosis in various cancers. These TAMs suppress the immune system and stimulate blood vessel formation thereby stimulating the growth of the tumor. On the other hand, there are also studies that show just the opposite effect, reaching the conclusion that TAMs have an anti-tumor effect.

The opposing functions of TAMs in the development of tumors arise the question whether there are specific factors within the micro-environment of the tumor which dictate the phenotype of these TAMs.

Neuropilin-1 (Nrp1)

Andrea Casazza and his colleagues, under the direction of Massimiliano Mazzone, studied the mechanism that is responsible for the opposing phenotypes of TAMs. Their study showed that the protein neuropilin-1 (Nrp1) is crucial for the localization of TAMs inside hypoxic tumor regions, which strengthens the pro-tumoral characteristics of TAMs.

Consequently, they discovered that by blocking Nrp1, macrophages were no longer able to migrate inside hypoxic regions in the tumor. It is in this way that the anti-tumoral activity of the macrophages is restored. Less suppression of the immune response and less in the tumor leads to less tumor growth.

Impact of this research

This pre-clinical study from Professor Mazzone and his colleagues reveals a new molecular axis that may offer interesting therapeutic opportunities for the treatment of pancreatic cancer, breast cancer and lung cancer, among others. The goal of a therapy like this is to restore the anti-tumor phenotype of

macrophages. After all, macrophages are cells that are normally part of our immune systems.

Furthermore, these results also have an important prognostic value—the positioning of macrophages in hypoxic tumor regions would be an indication of a poor prognosis, while the localization of macrophages in normoxic regions of the tumor could predict a better disease outcome.

Explore further: Depletion of 'traitor' immune cells slows cancer growth in mice

More information: This research appears in the journal Cancer Cell: Casazza et al., Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores anti-tumor immunity).

Related Stories

Depletion of 'traitor' immune cells slows cancer growth in mice

September 16, 2013
When a person has cancer, some of the cells in his or her body have changed and are growing uncontrollably. Most cancer drugs try to treat the disease by killing those fast-growing cells, but another approach called immunotherapy ...

Key driver of metastasis identified

October 31, 2011
Scientists at Dalhousie University in Nova Scotia have identified a key mechanism of metastasis that could lead to blocking tumor growth if their findings are confirmed.

Using CD47's protection to deliver anti-cancer drugs directly to tumor cells

October 9, 2012
(Medical Xpress)—For most of their natural lives, red blood cells hide safely under the radar of the body's immune system, thanks to a cloak of "don't eat me" protein called CD47. Ching-An Peng of Michigan Technological ...

Recommended for you

Vitamin C may encourage blood cancer stem cells to die

August 17, 2017
Vitamin C may "tell" faulty stem cells in the bone marrow to mature and die normally, instead of multiplying to cause blood cancers. This is the finding of a study led by researchers from Perlmutter Cancer Center at NYU Langone ...

Scientists develop novel immunotherapy technology for prostate cancer

August 17, 2017
A study led by scientists at The Wistar Institute describes a novel immunotherapeutic strategy for the treatment of cancer based on the use of synthetic DNA to directly encode protective antibodies against a cancer specific ...

Outdoor light at night linked with increased breast cancer risk in women

August 17, 2017
Women who live in areas with higher levels of outdoor light at night may be at higher risk for breast cancer than those living in areas with lower levels, according to a large long-term study from Harvard T.H. Chan School ...

Scientists develop blood test that spots tumor-derived DNA in people with early-stage cancers

August 16, 2017
In a bid to detect cancers early and in a noninvasive way, scientists at the Johns Hopkins Kimmel Cancer Center report they have developed a test that spots tiny amounts of cancer-specific DNA in blood and have used it to ...

Toxic formaldehyde is produced inside our own cells, scientists discover

August 16, 2017
New research has revealed that some of the toxin formaldehyde in our bodies does not come from our environment - it is a by-product of an essential reaction inside our own cells. This could provide new targets for developing ...

Cell cycle-blocking drugs can shrink tumors by enlisting immune system in attack on cancer

August 16, 2017
In the brief time that drugs known as CDK4/6 inhibitors have been approved for the treatment of metastatic breast cancer, doctors have made a startling observation: in certain patients, the drugs—designed to halt cancer ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.